RECURRENT PANCREATIC CARCINOMA
Clinical trials for RECURRENT PANCREATIC CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT PANCREATIC CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT PANCREATIC CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental drug cocktail targets Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests a combination of two targeted drugs (vismodegib and erlotinib) with or without standard chemotherapy (gemcitabine) in people with advanced pancreatic cancer or other solid tumors that cannot be removed by surgery. The main goal is to find the safest d…
Matched conditions: RECURRENT PANCREATIC CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 12:09 UTC
-
Triple-Drug cocktail targets Hard-to-Treat pancreatic cancer
Disease control OngoingThis early-phase study tested a combination of three drugs (gemcitabine, dasatinib, and erlotinib) in 19 people with advanced pancreatic cancer that had spread or could not be removed by surgery. The main goal was to find the safest dose and check for side effects. Researchers al…
Matched conditions: RECURRENT PANCREATIC CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:05 UTC
-
New drug duo shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-stage study tests a combination of two drugs, guadecitabine and durvalumab, in people with advanced liver, pancreatic, bile duct, or gallbladder cancer that has spread. The goal is to find the best dose and see if the combination is safe and can shrink tumors. About 55…
Matched conditions: RECURRENT PANCREATIC CARCINOMA
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
Gene test trial aims to outsmart advanced cancers
Knowledge-focused OngoingThis study tests whether analyzing the genes in a patient's tumor can help doctors choose a more effective treatment. Over 6,400 adults with advanced or hard-to-treat cancers (solid tumors, lymphoma, or myeloma) had their tumors genetically screened. Those with specific genetic c…
Matched conditions: RECURRENT PANCREATIC CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated May 22, 2026 13:51 UTC